FDA Cuts User Fees Across The Board For Generic, Brand Drugs

FDA announced that user fees for prescription drugs and biosimilars will decrease from fiscal year 2016 levels in all fee categories. Fees for abbreviated new drug applications and prior approval supplements will also decrease, while fees for all other generic user fee categories will increase. The agency released the prescription drug and biosimilar user fee rates on Wednesday (July 27) for fiscal year 2017, and released generic drug user fees for fiscal year 2017 on July 22. The fees are...